Literature DB >> 23133188

Advances and future directions in management of prostate cancer.

Louis S Krane1, Manish N Patel, Ashok K Hemal.   

Abstract

Despite the high cure rates of patients diagnosed and treated with prostate cancer, there is still room for improvement in management of these patients. This includes the identification of patients at highest risk for progression, the usage of focal therapies in low risk disease, and the continued improvement on established modalities. Through these avenues, the morbidity associated with treatment for prostate cancer can be vastly reduced, and thus patient outcomes improved. This article reviews the current treatment modalities and future directions for the treatment of localised prostate cancer.

Entities:  

Keywords:  Future directions; Localised; Prostate cancer

Year:  2010        PMID: 23133188      PMCID: PMC3452748          DOI: 10.1007/s12262-009-0091-7

Source DB:  PubMed          Journal:  Indian J Surg        ISSN: 0973-9793            Impact factor:   0.656


  29 in total

1.  Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer.

Authors:  E M Messing; J Manola; M Sarosdy; G Wilding; E D Crawford; D Trump
Journal:  N Engl J Med       Date:  1999-12-09       Impact factor: 91.245

2.  Potency following robotic radical prostatectomy: a questionnaire based analysis of outcomes after conventional nerve sparing and prostatic fascia sparing techniques.

Authors:  Mani Menon; Sanjeev Kaul; Akshay Bhandari; Alok Shrivastava; Ashutosh Tewari; Ashok Hemal
Journal:  J Urol       Date:  2005-12       Impact factor: 7.450

3.  The University of California, San Francisco Cancer of the Prostate Risk Assessment score: a straightforward and reliable preoperative predictor of disease recurrence after radical prostatectomy.

Authors:  Matthew R Cooperberg; David J Pasta; Eric P Elkin; Mark S Litwin; David M Latini; Janeen Du Chane; Peter R Carroll
Journal:  J Urol       Date:  2005-06       Impact factor: 7.450

4.  Updated nomogram to predict pathologic stage of prostate cancer given prostate-specific antigen level, clinical stage, and biopsy Gleason score (Partin tables) based on cases from 2000 to 2005.

Authors:  Danil V Makarov; Bruce J Trock; Elizabeth B Humphreys; Leslie A Mangold; Patrick C Walsh; Jonathan I Epstein; Alan W Partin
Journal:  Urology       Date:  2007-06       Impact factor: 2.649

5.  Clinical predictors of Gleason score upgrading: implications for patients considering watchful waiting, active surveillance, or brachytherapy.

Authors:  Girish S Kulkarni; Gina Lockwood; Andrew Evans; Ants Toi; John Trachtenberg; Michael A S Jewett; Antonio Finelli; Neil E Fleshner
Journal:  Cancer       Date:  2007-06-15       Impact factor: 6.860

6.  Evolution of robotic radical prostatectomy: assessment after 2766 procedures.

Authors:  Ketan K Badani; Sanjeev Kaul; Mani Menon
Journal:  Cancer       Date:  2007-11-01       Impact factor: 6.860

Review 7.  Brachytherapy for the treatment of prostate cancer.

Authors:  Jamie A Cesaretti; Nelson N Stone; Vassilios M Skouteris; Janelle L Park; Richard G Stock
Journal:  Cancer J       Date:  2007 Sep-Oct       Impact factor: 3.360

8.  Nomogram incorporating PSA level to predict cancer-specific survival for men with clinically localized prostate cancer managed without curative intent.

Authors:  Michael W Kattan; Jack Cuzick; Gabrielle Fisher; Daniel M Berney; Tim Oliver; Christopher S Foster; Henrik Møller; Victor Reuter; Paul Fearn; James Eastham; Peter T Scardino
Journal:  Cancer       Date:  2008-01-01       Impact factor: 6.860

9.  Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer.

Authors:  A V D'Amico; R Whittington; S B Malkowicz; D Schultz; K Blank; G A Broderick; J E Tomaszewski; A A Renshaw; I Kaplan; C J Beard; A Wein
Journal:  JAMA       Date:  1998-09-16       Impact factor: 56.272

10.  The influence of finasteride on the development of prostate cancer.

Authors:  Ian M Thompson; Phyllis J Goodman; Catherine M Tangen; M Scott Lucia; Gary J Miller; Leslie G Ford; Michael M Lieber; R Duane Cespedes; James N Atkins; Scott M Lippman; Susie M Carlin; Anne Ryan; Connie M Szczepanek; John J Crowley; Charles A Coltman
Journal:  N Engl J Med       Date:  2003-06-24       Impact factor: 91.245

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.